NCT07439341Not yet recruiting
AGE and CALLY Index in Familial Mediterranean Fever
Association Between Skin Autofluorescence-Measured Advanced Glycation End Products and the CALLY Index in Patients With Familial Mediterranean Fever: A Cross-Sectional Controlled Study
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks and persistent low-grade inflammation. Even during attack-free periods, subclinical inflammation may continue and contribute to long-term complications. Advanced glycation end products (AGEs) are molecules that accumulate under chronic inflammatory and oxidative stress conditions. AGEs can be measured non-invasively using skin autofluorescence (SAF). The C-reactive protein-albumin-lymphocyte (CALLY) index is a composite marker derived from routine laboratory parameters and reflects systemic inflammation and nutritional status. This observational cross-sectional study aims to evaluate the association between skin autofluorescence-measured AGE levels and the CALLY index in patients with FMF. The study will also compare AGE levels between FMF patients and age- and sex-matched healthy controls. The study does not involve any intervention, treatment assignment, or randomization. All laboratory parameters will be obtained from routine clinical evaluations, and AGE measurement will be performed using a non-invasive device.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 23 Feb 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- Bursa City Hospital
- Diseases
- Amyloidosis
- NCT number
- NCT07439341
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Feb 2026 to the primary completion date, 1 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of diabetes mellitus
- Chronic kidney disease stage 3 or higher
- Active infection
- Malignancy within the past 5 years
- Dermatologic condition affecting the forearm measurement site
- Any condition that, in the opinion of the investigators, may interfere with study participation
Other
- Use of high-dose antioxidant or vitamin supplementation within the past 3 months
Who the study is looking for
- For FMF Patients:
- Age between 18 and 65 years
- Diagnosis of Familial Mediterranean Fever according to Tel-Hashomer criteria
- At least 6 months of clinical follow-up
- Available routine laboratory data (CRP, albumin, lymphocyte count)
- Not in an acute FMF attack at the time of assessment
- Ability to provide written informed consent
- For Healthy Controls:
- Age between 18 and 65 years
- No history of chronic inflammatory, autoimmune, metabolic, or renal disease
- Ability to provide written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.